Synairgen’s SNG001 is a nebulizer containing interferon beta-1a that showed great promise in a recent Phase 2 trial. Volunteers who received the drug had greater odds of recovering from COVID-19 than placebo controls. The study did highlight a potential issue with the interferon therapy, as researchers found the drug favors the development of the kind …
The researchers who developed an interferon nebulizer for coronavirus patients have published promising results for a Phase 2 trial. The Synairgen SNG001 nebulizer helped hospitalized patients recover from COVID-19 faster than a group who received a placebo. A series of studies have shown that interferon may hold the key to preventing some COVID-19 deaths, as …
A coronavirus treatment involving nebulizers that can deliver aerosols directly to the lungs of infected COVID-19 patients is seen as a significant breakthrough that could be a game-changer for the management of the pandemic. Patients who inhaled interferon beta from a Synairgen nebulizer were significantly less likely to develop complications and experience shortness of breath …
